T細胞浸潤在肺腺癌發(fā)生中的意義以及與MicroRNA21的關系
[Abstract]:BACKGROUND The pathogenesis of lung cancer is still unknown, which is one of the causes of poor clinical prevention and treatment of lung cancer. Lung cancer has become a major dangerous disease endangering people's health. Signal transducers and activators of transcription (STAT) are many growth factors and thin cells in organisms. MicroRNA21 (microRNA21) is a non-coding small molecule RNA involved in the body's growth, metabolism, development and disease, and is associated with the occurrence, development, invasion and metastasis of a variety of tumors. The relationship between signal transduction among members of STAT family is becoming more and more interrelated, especially the interaction mechanism between microRNAs-21 and STAT3 signaling pathways is widely recognized. What is the significance of the Mi R-21/STAT3 signaling pathway in the development of lung cancer and the effect on T lymphocyte infiltration in the tumor environment? In this study, the expression of STAT3 and microRNA-21 in human lung adenocarcinoma was detected by quantitative real-time polymerase chain reaction (q RT-PCR), and the immersion of T4 and T8 cells in lung adenocarcinoma was detected by immunohistochemistry. Objective To investigate the relationship between the expression of STAT3 and microRNAs-21 in lung adenocarcinoma and the development of lung adenocarcinoma and the infiltration of T cells. Methods From June 2013 to June 2015, 46 specimens were collected from the Department of Laboratory Pathology, 91 Central Hospital of PLA, Department of Pathology, Jiaozuo People's Hospital, Henan Province. Lung adenocarcinoma tissues and paracancerous tissues, including 34 cases of metastatic carcinoma and 12 cases of normal lung tissues as negative control. The lung adenocarcinoma tissues, paracancerous tissues (about 2-5 cm away from the margin of the tumor tissue) and normal lung tissues were fresh tissue specimens and stored in refrigerator or liquid nitrogen at - 80 C. Lung adenocarcinoma tissues, paracancerous tissues The specimens collected did not include patients with lung adenocarcinoma who had undergone chemotherapy before operation or patients with recurrent lung adenocarcinoma. Results 1 46 cases of lung adenocarcinoma tissues were collected by routine pathological diagnosis, including 34 cases of lymph node metastatic carcinoma, 12 cases of normal lung tissues as control. All tissues were pathologically diagnosed. 2 STAT3 mRNA expression was detected by Q RT-PCR. The results of AT3 mRNA expression in the above tissues were as follows: normal lung tissue was 0.319+0.015; paracancerous tissue was 0.631+0.020; lung adenocarcinoma tissue was 1.046+0.042; metastatic cancer tissue was 1.235+0.015. There were significant differences in gene expression between normal lung tissue, para-lung cancer tissue, lung adenocarcinoma tissue and metastatic cancer tissue (P 0.01). The expression of STAT3 gene in lung adenocarcinoma was significantly higher than that in normal and adjacent tissues (P 0.01). 3 The expression of microRNA-21 in lung adenocarcinoma and normal lung tissues was detected by qRT-PCR. The results showed that the expression of microRNA-21 in all kinds of tissues in normal group was 0.0018 (+0.001). There were significant differences between normal lung tissues and lung adenocarcinoma tissues (P 0.01). There were significant differences between lung adenocarcinoma and metastatic carcinoma tissues (P 0.05). The expression of microRNA-21 in normal lung tissues was low, and that in lung adenocarcinoma tissues was high (P 0.05). The proportion of CD3 +, CD4 +, CD8 + lymphocytes in tumor tissues was 76.12% in normal tissues. The number of CD3 + cells in tumor tissues was 76.12% in paracancerous group and normal group. There was no significant change in paracancerous group, but the number of CD4 + cells in adenocarcinoma group was significantly decreased. The proportion of CD4 + cells in normal group was 45.17%, and that in paracancerous and adenocarcinoma group was lower than normal group. The number of CD8 + cells in normal group was 28.78%, and that in adenocarcinoma group was higher than that in normal group, P 0.05. Conclusion The occurrence and evolution of lung adenocarcinoma may be related to the increase of microRNA-21 and the disturbance of immune function in vivo.
【學位授予單位】:新鄉(xiāng)醫(yī)學院
【學位級別】:碩士
【學位授予年份】:2016
【分類號】:R734.2
【相似文獻】
相關期刊論文 前10條
1 常秀青 ,Tony Sheldon;低焦油含量香煙與肺腺癌發(fā)病率上升有關[J];英國醫(yī)學雜志(中文版);2002年01期
2 鄧小梅,何權瀛;細支氣管肺泡細胞癌與其他類型肺腺癌的對比分析[J];中國呼吸與危重監(jiān)護雜志;2005年03期
3 楊長青;王蓮芳;;飛行人員右肺腺癌1例[J];海軍醫(yī)學雜志;2006年04期
4 陳小兵;閆明;羅素霞;李寧;鄒宏志;韓黎麗;;84例青年肺腺癌早期誤診原因分析[J];實用診斷與治療雜志;2007年09期
5 陳小兵;閆明;曾軍杰;羅素霞;;青年女性肺腺癌首發(fā)癥狀及早期誤診原因分析[J];中國現(xiàn)代醫(yī)生;2009年06期
6 周琪;段亮;姜格寧;丁嘉安;;青年男性肺腺癌臨床特征對預后的影響[J];中國癌癥雜志;2009年08期
7 張文麗;;以高熱為首發(fā)癥狀的肺腺癌病例并文獻復習[J];甘肅醫(yī)藥;2013年07期
8 郭哲;肺腺癌病人的預防性頭顱照射[J];國外醫(yī)學(腫瘤學分冊);1988年06期
9 劉福升,,李險峰,楊愛民,王彤;肺腺癌誤診肺結核16例分析[J];中國防癆雜志;1994年01期
10 余偉江;放療及合并化療治療Ⅲ期肺腺癌療效分析[J];腫瘤防治研究;1994年04期
相關會議論文 前10條
1 孫強;顧春東;雷霆;王金;李錦繡;;浸潤性周圍型小肺腺癌(≤2cm)不同病理亞型的比較[A];第13屆全國肺癌學術大會論文匯編[C];2013年
2 袁明遠;;周圍型肺腺癌病灶的放射學分類及其臨床價值[A];中華醫(yī)學會第16次全國放射學學術大會論文匯編[C];2009年
3 顧國浩;;生物芯片在肺腺癌診斷中的應用進展[A];中華醫(yī)學會第八次全國檢驗醫(yī)學學術會議暨中華醫(yī)學會檢驗分會成立30周年慶典大會資料匯編[C];2009年
4 林嘉穎;吳一龍;楊學寧;喬貴賓;王坤;陳剛;;不同預后的肺腺癌患者酪氨酸激酶信號傳導通路異常的初步探討[A];第三屆中國腫瘤學術大會教育論文集[C];2004年
5 湯秀英;吳立紅;張燁;;肺腺癌的超微觀察及異質性探討[A];第八次全國電子顯微學會議論文摘要集(Ⅰ)[C];1994年
6 徐芝君;應可凈;;胸部CT基本正常肺腺癌伴慢性DIC一例并文獻復習[A];浙江省醫(yī)學會呼吸系病分會成立三十周年慶典活動暨2008年呼吸病學學術年會論文匯編[C];2008年
7 邵艷;洪偉俊;寧允葉;胥武劍;李強;;肺腺癌惡性轉化相關蛋白的初步篩查[A];中華醫(yī)學會呼吸病學年會——2011(第十二次全國呼吸病學學術會議)論文匯編[C];2011年
8 王恩華;;解讀及評價國際多學科肺腺癌分類[A];2012年浙江省病理學學術年會論文集[C];2012年
9 宋正波;朱慧能;郭振英;吳偉;孫文勇;張沂平;;肺腺癌新分類在預測Ⅰ期非小細胞肺腺癌預后中的價值[A];第13屆全國肺癌學術大會論文匯編[C];2013年
10 趙燕妮;曹菊;牟向東;闕呈立;;肺腺癌影像反復波動病例報告一例并文獻復習[A];中華醫(yī)學會呼吸病學年會——2013第十四次全國呼吸病學學術會議論文匯編[C];2013年
相關重要報紙文章 前8條
1 丁香;日發(fā)現(xiàn)肺腺癌的預測因子[N];中國醫(yī)藥報;2007年
2 仇逸邋孫國根;吸煙丈夫的妻子,患肺腺癌風險高[N];新華每日電訊;2007年
3 曾理;肺腺癌早診研究關注“起源”[N];健康報;2008年
4 記者 李天舒 胡德榮;為何不吸煙者也患肺癌[N];健康報;2010年
5 記者 胡德榮;非吸煙肺腺癌人群致癌基因突變譜建立[N];健康報;2011年
6 高原;或與MiR-21分子有關[N];廣東科技報;2009年
7 海飛魚;探索肺癌突變基因[N];醫(yī)藥經(jīng)濟報;2008年
8 健康時報記者 王志勝;一樣的腫瘤,不一樣治法[N];健康時報;2009年
相關博士學位論文 前10條
1 孫正亮;肺腺癌的分子分型特征及其與病理分型的關聯(lián)研究[D];復旦大學;2014年
2 朱聰惠;miR-183負調控下游靶基因PTPN4促進肺腺癌始動細胞侵襲遷移作用的研究[D];第三軍醫(yī)大學;2016年
3 董瑜;中國人群肺腺癌驅動基因表達與臨床特征及預后的相關性研究[D];上海交通大學;2013年
4 潘元威;肺部局灶性磨玻璃結節(jié)的~(18)F-FDG PET/CT表現(xiàn)與組織病理及EGFR基因突變的相關性研究[D];鄭州大學;2016年
5 楊欣;肺腺癌預后相關的臨床病理因素分析及分子病理研究[D];北京協(xié)和醫(yī)學院;2014年
6 鄭華;篩選肺腺癌相關血清自身抗體標志物[D];北京市結核病胸部腫瘤研究所;2010年
7 張揚;肺腺癌致癌基因突變研究[D];復旦大學;2013年
8 張麗;基于IASLC/ATS/ERS國際多學科新分類的肺腺癌影像學及相關研究[D];北京協(xié)和醫(yī)學院;2014年
9 楊繼要;肺腺癌腫瘤相關抗原的篩選鑒定及克隆表達[D];鄭州大學;2006年
10 何萍;染色體15q25.1區(qū)域基因多態(tài)性與中國南方人群肺腺癌易感性的關聯(lián)研究[D];南方醫(yī)科大學;2014年
相關碩士學位論文 前10條
1 卜靜;順鉑聯(lián)合雷帕霉素、3-MA對肺腺癌A549細胞及其裸鼠原位移植瘤的影響[D];河北醫(yī)科大學;2015年
2 Suraj Tamang(蘇拉杰塔芒);肺部呈GGN表現(xiàn)的非浸潤性病變與浸潤性肺腺癌的CT征象對比研究[D];大連醫(yī)科大學;2015年
3 張曄;1.5T磁共振表觀擴散系數(shù)早期監(jiān)測肺腺癌靶向治療療效的臨床價值[D];蘇州大學;2015年
4 楊太平(Prashanta Acharya);肺腺癌伴結節(jié)GGO:HRCT影像學和病理學的相關性[D];東南大學;2015年
5 宋雪薇;肺腺癌血清腫瘤標志物與EGFR突變及TKIs療效的相關性研究[D];大連醫(yī)科大學;2015年
6 明星;肺磨玻璃結節(jié)CT征象對早期肺腺癌診斷價值的Meta分析[D];遵義醫(yī)學院;2016年
7 孟誼;CastPCR法檢測EGFR驅動突變在肺癌中的初步應用探討[D];南京大學;2015年
8 任保瑞;ⅠB-ⅢA期肺腺癌患者中EGFR、KRAS基因突變狀態(tài)對術后應用培美曲塞聯(lián)合鉑類輔助化療療效的影響[D];安徽醫(yī)科大學;2016年
9 孔麗麗;肺腺癌中EZH2、MMP-28的表達和EGFR突變的關系及臨床意義[D];吉林大學;2016年
10 周欣可;雙源CT雙能量成像技術與肺腺癌病理分級相關性及其價值的初步研究[D];廣西醫(yī)科大學;2016年
本文編號:2199147
本文鏈接:http://sikaile.net/yixuelunwen/zlx/2199147.html